Clinical trial opens, targeting household members of those recently diagnosed with COVID-19

Regeneron antibody treatment will be studied to determine whether it can prevent infection.
Oct. 27, 2020

Aurora, Colo. (Oct 26, 2020) – UCHealth University of Colorado Hospital is recruiting family or household members living with someone who has been recently diagnosed with COVID-19. Late-stage clinical trials are now ongoing for REGN-COV2, Regeneron’s investigational anti-viral antibody cocktail for the treatment and prevention of COVID-19.

In the phase 3 trial, University of Colorado Hospital on the Anschutz Medical Campus will examine whether REGN-COV2 may prevent infection in people who have had close exposure to someone diagnosed with COVID-19, including members of that person’s household. REGN-COV2 consists of two potent, complementary, virus-neutralizing antibodies.

Since this trial focused on prevention of infection, enrollment for interested participants needs to happen quickly for the effectiveness of this study.

“The goal is to see if early use of the monoclonal antibody prevents infection in those not yet positive or reduces the severity in those who are positive but not yet symptomatic. Potential participants need to be enrolled within 96 hours of the collection of the positive test, so if people are interested they need to be in touch right away,” said Dr. Brian Montague, an infectious disease physician with the University of Colorado School of Medicine, who is leading the trial.

Eligible participants for the Regeneron study are adults living with an adult or child diagnosed with COVID-19 who are not sick enough to be in the hospital, but rather, are recuperating at home and quarantined with the illness.

This study will compare use of the antibodies to a placebo. Participants have a 50% chance of receiving the antibody cocktail. Participants will receive study-related medication and medical exams at no cost, as well as compensation for time and travel.

UCH has participated in about 40 COVID-19 clinical trials since the onset of the pandemic, thanks to the work of the CU Anschutz Medical Campus research teams and their tireless work to conduct these groundbreaking studies.

Those interested in the study can be screened rapidly using the online screening resource here.

Interested persons can also contact the study team during regular business hours (8 a.m. to 5 p.m. Monday through Friday) at 720-335-5205, or email cucovidantibodystudy@gmail.com.

About the author


ADVERTISEMENT